Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
:LCTX
LCTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.47 - $1.61
Previous CloseN/A
Volume522.43K
Average Volume (3M)1.46M
Market Cap
$113.40M
Enterprise Value$139.60M
Total Cash (Recent Filing)$45.79M
Total Debt (Recent Filing)$2.51M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 08, 2025EPS Estimate
-0.03Last Dividend Ex-Date
Nov 29, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding228,356,300
10 Day Avg. Volume2,161,015
30 Day Avg. Volume1,463,534
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.18
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.23
Enterprise Value/Ebitda-6.69
Forecast
1Y Price Target
$4.00Price Target Upside700.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Lineage Therap News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsGenentech moving into a randomized controlled trial could trigger warrants worth an additional $36M in gross proceeds.
PartnershipsRoche's backing keeps Lineage well ahead in clinical progress, building momentum in the field.
Research And DevelopmentPreclinical testing of a new thaw and inject formulation of OPC1 demonstrated functional recovery and improvement in gait coordination and motor performance.
Bears Say
Financial PerformanceThe company's 12-month price target has been lowered due to dilution from recent financing activities.
Investment RisksEven modest signals of efficacy from the study could warrant additional evaluation, highlighting the potential impact on spinal cord injury treatment.
Market SentimentThe start of the Phase 2 DOSED study brings OPC1 back into the clinic, aiming to improve on positive prior clinical effects in spinal cord injury patients.
---
Ownership Overview
53.70% Insiders
6.38% Mutual Funds
0.79% Other Institutional Investors
32.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.47 and its highest was $1.61 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $113.40M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 40 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Mar 10, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.03 by $0.01.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. pays a Notavailable dividend of $0.112 which represents an annual dividend yield of N/A. See more information on Lineage Cell Therapeutics, Inc. dividends here
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 228,356,300 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.03. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
---
Lineage Therap Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (700.00% Upside)
$4.00 (700.00% Upside)
Hedge Fund Trend
Increased
By 9.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $6.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.57%
12-Months-Change
Fundamentals
Return on Equity
-26.25%
Trailing 12-Months
Asset Growth
12.08%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
---
LCTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive advancements in the OpRegen program and manufacturing capabilities, alongside financial challenges and ongoing development hurdles in the OPC1 program. The progress in partnerships and potential additional funding weigh positively, but the financial losses and program challenges balance the sentiment.Read More>---
LCTX Stock 12 Month Forecast
Average Price Target
$4.00
▲(700.00% Upside)
Technical Analysis
Mesoblast
―
Bluebird Bio
―
Fate Therapeutics
―
Sorrento Therapeutics
―
Cara Therapeutics
―
Best Analysts Covering LCTX
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
+10.96%
reiterated a buy rating 3 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +10.96% per trade.
---